EGFR-targeted antibody-toxin conjugate extends survival in recurrent glioma
A phase 1 glioma trial found D2C7-ATC was tolerable and linked to longer survival in a subset of IDHwt recurrent glioblastoma patients.
This section contains the website’s posts.